Liver Cancer News

Blue Faery



Liver Cancer News

Print Friendly, PDF & Email

Click on the title to read the rest of the Liver Cancer News story.

FDA Approves Nivolumab For Treating Liver Cancer
26 September 2017
The US Food and Drug Administration (FDA) has granted accelerated approval to nivolumab (Opdivo) for the treatment of patients with Hepatocellular Carcinoma (HCC) who have previously received sorafenib. The recommended dose is 240 mg delivered intravenously over a 60-minute infusion every two weeks, until either disease progression or unacceptable toxicity. “Unfortunately, the majority of HCC patients are diagnosed with advanced-stage disease and are not candidates for potentially curative surgical interventions,” said Adrian M. Di Bisceglie, MD, of the Saint Louis University Liver Center, in a press release. “More options are needed for advanced-stage HCC patients who have failed prior systemic therapy.”

FDA Accepts Lenvatinib Application For Advanced HCC
26 September 2017
The FDA has accepted a supplemental new drug application for lenvatinib (Lenvima) as a frontline systemic treatment for patients with advanced Hepatocellular Carcinoma (HCC), according to a statement from the company developing the therapy, Eisai. Under a standard review, the FDA will render a decision within 10 months.

Therapeutic Advancements Changing Liver Cancer Paradigm
25 September 2017
For nearly a decade after the 2007 approval of sorafenib (Nexavar), there were no new therapies approved for HCC. However, there are now new drugs showing promise, according to Steven R. Alberts, MD. In April 2017, the FDA approved regorafenib (Stivarga), a small-molecule multikinase inhibitor, as a second-line treatment for patients with HCC who had previously received sorafenib.

Reduce Alcohol By A Liter A Year, See A 15 Per Cent Reduction In Liver Cancer
25 September 2017
Reducing Australia’s per-capita alcohol consumption by just one liter a year would drive a significant reduction in head, neck and liver cancer deaths. That’s the conclusion of a new study that offers the first suggestive evidence that a decrease in Australia’s population-level drinking — as opposed to individual-level — would reduce the prevalence of cancer deaths particularly among men and over 50s.

Hepatocellular Carcinoma: Current Thoughts On Liver Transplantation
25 September 2017
LIVER TRANSPLANT offers the highest rates of long-term survival for patients with Hepatocellular Carcinoma, according to Maria Russell, MD, Assistant Professor of Surgery at Emory University, Atlanta. At the 2017 Debates and Didactics in Hematology and Oncology Conference at Sea Island, Georgia, Dr. Russell described the latest trends in liver transplantation. The other potentially curative option is surgical resection, and choosing between the two modalities is not always simple. “Patients don’t always fall into nice slots,” she admitted. If both modalities are available to the patient with Hepatocellular Carcinoma, selection takes into account the degree of cirrhosis, the size and number of lesions, the presence of portal hypertension and comorbidities, and insurance/citizenship status.

Unmet Needs In Systemic Therapy For Liver Cancer
21 September 2017
In the past year, there have been many negative trials in HCC, both in first-line and in second-line. The first positive trial was with sorafenib, which was published in 2008. Moreover, many investigators thought that treatment with sorafenib could clearly be improved with other tyrosine kinase inhibitors. And sorafenib was always considered as a low-hanging fruit, as well as treatment in second-line where we only have best supportive care.

Mayor Rogers Announces He Has Stage 4 Liver Cancer, Will Continue Role As Mayor
20 September 2017
Surrounded by his City Council colleagues and the media, Burbank Mayor Will Rogers announced on Wednesday that he has been diagnosed with stage 4 liver cancer and non-alcoholic cirrhosis. “Like every one of us here today, I don’t know if I have another week or another five weeks,” Rogers said during a press conference on the steps of City Hall. For the last two years, Rogers, 60, said his doctors have diagnosed him and have cleared him of any cancer four times, but his recent diagnosis of Hepatocellular Carcinoma, one of the most common forms of liver cancer, was much more serious than the rest.

Initial Treatment Decisions In Liver Cancer
19 September 2017
When we make a diagnosis of metastatic disease at the moment, we do not really have so many treatment options. In general, and if you look at most guidelines, we would recommend systemic therapies. However, this might not always be required. And I think it really depends on the extent of metastatic disease. Sometimes we have patients who just have small lymph nodes, like one or two metastases in the lung, and the main tumor burden in the liver. I think these patients are also candidates for local therapies — with all the caution I have mentioned before, that we should not overuse local therapies. But I think we should also not underuse local therapies. There could be a mixture.

Does Reducing The Starting Dose Of Sorafenib Affect Outcomes In Hepatocellular Carcinoma?
19 September 2017
In a retrospective study reported in the Journal of Clinical Oncology, Reiss et al found that reducing the starting dose of sorafenib (Nexavar) was associated with noninferior overall survival, reduced cost, and lower risk of discontinuing treatment in patients with advanced Hepatocellular Carcinoma.

Study Shows DAAs Are Not Associated With Increased HCC Recurrence Risk
18 September 2017
Direct acting antivirals (DAA) are a novel and completely oral hepatitis C therapy that is associated with a high response rate. DAAs are used in most patients being treated for hepatitis C, including those with decompensated cirrhosis. This type of treatment has now completely replaced interferon-based therapy for patients with hepatitis C, a therapy that was also associated with a decrease in Hepatocellular Carcinoma (HCC) incidence in 40% to 50% of patients.

Lenvatinib Continues To Show Noninferiority To Sorafenib In Liver Cancer
17 September 2017
First-line therapy with lenvatinib (Lenvima) continued to be noninferior in overall survival (OS) and achieve significant improvements in progression-free survival (PFS), time to progression, and objective response rate (ORR) compared with sorafenib (Nexavar) for patients with unresectable Hepatocellular Carcinoma (HCC), according to updated phase III results presented at the 11th Annual International Liver Cancer Association Conference.

BLU-554 Associated With Improved Response In HCC
17 September 2017
BLU-554, a potent and highly selective inhibitor of fibroblast growth factor receptor 4 (FGFR4), induced an overall response rate of 16% (95% CI, 6 – 31) in patients with FGF 19 immunohistochemistry (IHC)-positive Hepatocellular Carcinoma (HCC), according to findings presented at the 11th Annual Conference of the International Liver Cancer Association in Seoul, South Korea.

STORM Study Fails To Find Predictive Biomarkers For Sorafenib In HCC
16 September 2017
Hepatocyte pERK-positive immunostaining and microvascular invasion were independent prognostic factors of recurrence-free survival (RFS) for patients with Hepatocellular Carcinoma (HCC) treated with adjuvant sorafenib (Nexavar); however, a predictive biomarker for recurrence was not uncovered, according to an analysis of the phase III STORM study presented at the 11th International Liver Cancer Association Annual Conference.

Precision Screening May Improve Surveillance In HCC
16 September 2017
During a presentation at the 2017 International Liver Cancer Association Annual Conference, Amit G. Singal, MD, MS, stressed that precision screening for Hepatocellular Carcinoma (HCC) could improve on current screening techniques through its risk-stratifying approach. The current standard of care for HCC surveillance is ultrasound with or without serum biomarker including alpha-fetoprotein. Not only is this approach highly operator-dependent, but patient characteristics such as obesity, liver nodularity and echogenicity, and presence of ascites can limit accuracy.

Finn Highlights Practice-Changing Studies In Liver Cancer
15 September 2017
The 11th International Liver Cancer Association (ILCA) Annual Conference, taking place September 15 to 17 in Seoul, South Korea, is showcasing multidisciplinary findings across the field of Hepatocellular Carcinoma. Pivotal research on VEGF inhibitors, immunotherapy regimens, and biomarkers are among the much-discussed abstracts at this year’s ILCA conference.

Hong Kong Study Shows HBV Treatment Reduces Liver Cancer Incidence
14 September 2017
Hepatitis B virus (HBV) treatment is confirmed an effective way to reduce liver cancer incidence, according to a study by the University of Hong Kong which made the results public on Thursday.
The university’s research team obtained 14-year (from 1999 to 2012) HBV treatment data in specialist outpatient clinics in Hong Kong and statistically studied the effect of HBV treatment on liver cancer trends. It is found that HBV treatment is associated with a reduction in overall liver cancer incidence, and the effect is the most obvious among the age group of 55 – 64 years.

Algae Blooms Linked To Liver Cancer
14 September 2017
An Ohio State University study recently found that people in areas with blue-green algae blooms are more likely to die from non-alcohol related liver disease. Dr. Edie Widder with the Ocean Research and Conversation Association (ORCA) says there are several ways how you can absorb the dangerous toxins. “It was crazy for people to be out water skiing”,” Widder said, referring to a major bloom last year in Martin County, Florida. “That’s one of the best ways you can ever take up these toxins.”

Role Of TACE In Liver Cancer
12 September 2017
Oliver Waidmann, MD: Locoregional therapies are the standard of care in intermediate-stage HCC, so-called BCLC-B patients. I think the most important and most familiar used treatment option is so-called transarterial chemoembolization, or TACE. TACE is an appropriate choice in every patient who has local and regional disease, so-called BCLC-B disease. You can do it even in some patients with BCLC-C stage, but with these patients, you should not have an infiltration of the main portal vein and you should not have complete portal vein thrombosis. These patients are, in principle, eligible for TACE, but you have to consider that the patients, if they have decrease of liver function after 1 or 2 cycles of TACE, won’t benefit from further cycles and then you should switch to another treatment option.

Lenvatinib May Delay Functional Deterioration In Hepatocellular Carcinoma
12 September 2017
Lenvatinib may delay deterioration and improve health-related quality of life (HRQOL) outcomes among patients with unresectable Hepatocellular Carcinoma (HCC) compared with sorafenib, according to a study presented at the European Society for Medical Oncology (ESMO) 2017 Congress. In the phase 3, non-inferiority REFLECT study ( Identifier: NCT01761266), researchers compared the safety and efficacy of lenvatinib with sorafenib. The purpose of this secondary analysis was to evaluate the effect the study treatments would have on HRQOL. Nine hundred and fifty-four patients with unresectable HCC were randomly assigned 1:1 to receive lenvatinib or sorafenib.

Researchers Discover Major Mechanism In Development Of Liver Cancer
11 September 2017
An international team of researchers headed up by UZH Professor Achim Weber from the Institute of Pathology and Molecular Pathology of the University Hospital Zurich and Mathias Heikenwälder, professor at the German Cancer Research Center in Heidelberg, Germany, has discovered a major mechanism in the development of liver cancer. One of the main players in this process is enzyme caspase-8, which assumes an important dual role.

Onxeo Announces Top-Line Results From Relive Phase III Study Of Livatag® In Advanced Hepatocellular Carcinoma
11 September 2017
Onxeo S.A., a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced top line results from the phase III ReLive trial of Livatag® (doxorubicine Transdrug™) in adult patients with unresectable Hepatocellular Carcinoma (HCC), intolerant to sorafenib or having progressed after a systemic therapy including sorafenib, when compared to best standard of care. The study did not meet its primary endpoint of improving survival over the comparative group.

A Bangladeshi Researcher At The Forefront Of Fight Against Liver Cancer
10 September 2017
Dr. Devanand Sarkar’s groundbreaking research that uncovered the mechanism of development of liver cancer is now in the spotlight once again. His new research is close to bringing about new treatments for liver cancer. Dr. Sarkar and his colleagues had originally discovered and cloned AEG-1 gene, which was overexpressed in liver cancer and made cancer cells resistant to chemotherapy. His team also discovered another gene called SND1, which also promotes liver cancer. After discovering the mechanism, he developed therapeutic approach including nanoparticle-based therapy and other drug that successfully blocked both of these genes in mouse model.

Blueprint Medicines Announces New Data From Ongoing Phase 1 Clinical Trial Of BLU-554 In Patients With Advanced Hepatocellular Carcinoma
10 September 2017
CAMBRIDGE, Mass. Blueprint Medicines Corporation, a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced updated data from its ongoing Phase 1 clinical trial of BLU-554, a potent and highly selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) for the treatment of patients with advanced Hepatocellular Carcinoma (HCC). As of a data cutoff date of August 18, 2017, BLU-554 demonstrated a 16 percent objective response rate (ORR) in patients with FGFR4-driven HCC. In addition, 49 percent of patients with FGFR4-driven HCC had radiographic tumor reduction. BLU-554 was well tolerated and most adverse events (AEs) reported by investigators were Grade 1 or 2. The data will be presented today in an oral presentation at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain.

Hepatocellular Carcinoma: Resection Vs. Transplantation
8 September 2017
Liver transplantation is the gold standard for treating early hepatocellular cancers. Because of the lack of donors, this option is, however, available to a limited degree only. Curative liver resection is an alternative in this setting. Markus B. Schoenberg, Julian N. Bucher, and coauthors investigated whether liver resection (LR) can yield results that are comparable to those of liver transplantation.

Conclusion of development collaboration agreement for Opdivo® (nivolumab) and Lenvima® (lenvatinib mesylate) combination therapy for treatment of Hepatocellular Carcinoma
8 September 2017
Ono Pharmaceutical Co., Ltd. (Headquarters: Chuo-ku, Osaka, Representative Director and President: Gyo Sagara, “Ono”) and Eisai Co., Ltd. (Headquarters: Bunkyo-ku, Tokyo, CEO: Haruo Naito, “Eisai”) have announced that they have entered into a collaboration agreement to jointly develop the combination therapy of Ono’s human anti-human PD-1 (programmed cell death-1) monoclonal antibody, Opdivo® (nivolumab) and Eisai’s multi-kinase inhibitor, Lenvima® (lenvatinib mesylate) for the treatment of Hepatocellular Carcinoma (HCC). Based on this agreement, Ono and Eisai will swiftly implement a Phase Ib clinical trial in Japan to investigate the safety, tolerability, and efficacy of the combination of Opdivo and Lenvima in patients with HCC. Details relating to the financial and other conditions of this agreement are confidential.

Words Of Wisdom For Patients With Liver Cancer
8 September 2017
Andrea J. Wilson, president and founder of Blue Faery: The Adrienne Wilson Liver Cancer Association, offers advice for patients with liver cancer. Wilson started the foundation after her younger sister, Adrienne, died of liver cancer. First and foremost, Wilson wants patients to know that liver cancer is not their fault. Liver cancer is a “silent killer” and often not diagnosed until the later stages, but regardless of a person’s diagnosis or lifestyle, Wilson emphasized that she wouldn’t wish this disease on anyone. Next, she encouraged people to visit for resources and information on the disease.

Liver Cancer Screening Strategies
8 September 2017
For patients with HCC, early diagnosis is really, really important, because if they have a tumor in an early stage, you can really do a curative treatment for these patients — namely resection, ablation, or liver transplantation. All patients should get screening, and the most important is that patients with liver fibrosis, and even advanced cirrhosis, get regular treatment. So, we have a big problem. We have increasing rates of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. And, of course, we will get more and more patients. In the Western world, 30% of patients have fatty liver disease, and, of course, we cannot do screening in all patients. But we have to do some kind of risk adaption for these patients.

Comorbidities And Management Of HCC
8 September 2017
Patients with HCC usually have underlying liver diseases and most of them eventually develop liver cirrhosis. And currently, we can assume that around 70% to 80% of patients with HCC have an underlying liver fibrosis or liver cirrhosis. But this might change in the future because we have learned that in some chronic liver diseases, you really require cirrhosis to develop the HCC or it’s very closely correlated like in HCV, for example. But in other diseases like hepatitis B infection, nonalcoholic steatohepatitis, or fatty liver disease, the tumor can also develop in a nonfibrotic and noncirrhotic liver. So, at the moment, most of our patients do have liver fibrosis and cirrhosis, but with a shift in the underlying liver diseases, we might see more patients who do not have liver cirrhosis.

Coffee Consumption Associated With Reduced Liver Cancer Risk, No Link To Biliary Tract Cancer
7 September 2017
Increased coffee consumption is associated with a decreased risk of liver cancer, but there is no evident association between coffee consumption and risk of biliary tract cancer, according to data published in Nutrients. Justyna Godos, MSc, from the Department of Medical and Surgical Sciences and Advanced Technologies at the University of Catania in Catania, Italy, and colleagues conducted a meta-analysis that included 5 studies examining the risk of biliary tract cancer and 13 studies on liver cancer risk. The researchers assessed the dose-response relationship with a restricted cubic spline model and multivariate random-effect meta-regression.

Eisai To Present New Data For Lenvatinib In Hepatocellular Carcinoma And Renal Cell Carcinoma At ESMO 2017 Congress
4 September 2017
Eisai announced today clinical trial data from their oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain, being held on 8th – 12th September 2017. This will include data for lenvatinib in unresectable Hepatocellular Carcinoma (uHCC) and renal cell carcinoma (RCC). An analysis of the pivotal Phase III REFLECT trial (Study 304) showing lenvatinib data on health-related quality of life and disease symptoms in patients with uHCC versus treatment with sorafenib will be presented in an oral proffered paper session on Sunday 10th September.[1] This additional information follows the results presented at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, which demonstrated the treatment effect of lenvatinib on overall survival by statistical confirmation by non-inferiority to sorafenib, after many failed global Phase III trials involving multiple agents studied against sorafenib in advanced HCC.[2] For a decade there has been no new approved medication in the first-line systemic treatment of uHCC in Europe[3],[4]; Eisai submitted marketing authorization to the European Medicines Agency, based on the REFLECT study.

Researchers Developing Rapid, Cheap Liver Cancer Test
3 September 2017
University of Utah researchers say they are designing a diagnostic method that will be able to accurately identify signs of liver cancer within minutes, saving critical time for patients of the stealthy disease. The new type of test could forever change how people screen for the disease, said Marc Porter, a U. chemical engineering and chemistry professor who is leading the research along with Dr. Courtney Scaife, a surgeon who both practices and teaches surgery for the university. Porter said the long-term vision is for the tool itself to become as automatic and portable as a pregnancy test, though additional technology — called a spectrometer — is currently needed to precisely measure the results of the test. “It’s really compact, it’s simple and low cost,” he said of the test kit.

HEALTH MATTERS: Innovative Treatments Target Liver Cancer
1 September 2017
Did you know that the incidence of primary liver cancer has more than tripled since 1980? More than 40,000 Americans will be diagnosed with primary liver cancer this year, according to the American Cancer Society. And thousands of others will be diagnosed with secondary (metastatic) liver cancer, cancer that spreads to the liver after starting somewhere else in the body. While surgery remains the gold standard for treating liver cancer, advances in medicine have made more treatment options available, especially for patients who may not be able to tolerate surgery or in cases where tumors are too large to be removed safely.

Bayer To Highlight New Research At ESMO 2017 Congress
1 September 2017
Bayer will present the latest research from across its growing oncology portfolio at the European Society for Medical Oncology (ESMO) 2017 Congress, September 8 – 12 in Madrid, Spain. The studies presented will include new preclinical and clinical data on Bayer’s marketed portfolio and late-stage compounds as well as research from two earlier pipeline projects. Exploratory analysis of baseline microsatellite instability (MSI) status in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) or placebo in the phase 3 CORRECT trial. Circulating miRNA biomarkers predicting regorafenib (REG) clinical benefit in patients with Hepatocellular Carcinoma (HCC) in the RESORCE trial.

Discovery Of Drug Combination: Overcoming Resistance To Targeted Drugs For Liver Cancer
31 August 2017
A KAIST research team presented a novel method for improving medication treatment for liver cancer using Systems Biology, combining research from information technology and the life sciences. Professor Kwang-Hyun Cho in the Department of Bio and Brain Engineering at KAIST conducted the research in collaboration with Professor Jung-Hwan Yoon in the Department of Internal Medicine at Seoul National University Hospital. This research was published in Hepatology in September 2017. Liver cancer is the fifth and seventh most common cancer found in men and women throughout the world, which places it second in the cause of cancer deaths. In particular, Korea has 28.4 deaths from liver cancer per 100,000 persons, the highest death rate among OECD countries and twice that of Japan.

Higher FIB-4 Index In Patients With HBV Linked To Increased HCC Risk
31 August 2017
In a cohort of patients with chronic hepatitis B without cirrhosis, the risk for Hepatocellular Carcinoma was significantly higher among those with a FIB-4 index over 1.29, according to recently published data. “Implementation of HCC surveillance is important because it is the only way to identify HCC at an early stage, which reduces disease-related morbidity and mortality,” Tai-Chung Tseng, MD, PhD, from the National Taiwan University Hospital Jinshan Branch, and colleagues wrote. “On the basis of our data, the patients with baseline FIB-4 index [lower than] 1.29 and a favorable clinical profile did not develop HCC within 16 years of follow-up. This finding helps practicing physicians identify the patients with the lowest HCC risks, who may not have additional benefit from HCC surveillance.”

Liver Cancer Risks Not Affected By Hepatitis C Eliminating Therapy
29 August 2017
Hepatitis C virus (HCV) patients faced a similar risk of developing liver cancer whether they eradicated the virus with direct-acting antiviral (DAA) drugs or interferon therapy, researchers in Japan found. Yuko Nagaoki and colleagues at Hiroshima University compared the occurrence of Hepatocellular Carcinoma (HCC) in HCV patients cured with DAAs and those given pegylated interferon with ribavirin (PEG-IFN/RBV). Treating chronic HCV is important because the virus is a leading cause of cirrhosis, liver failure and HCC. “The goal of chronic HCV infection treatment is eradication of the virus in order to prevent HCC development,” Nagaoki, an assistant professor at, and her team wrote in a paper regarding the study.

Give First Dose Of Hepb Vaccine Within 24 Hours Of Birth: AAP
28 August 2017
Infants who weigh at least 2,000 grams (g) should receive their first dose of hepatitis B (HepB) vaccine within the first 24 hours of life, according to a new AAP policy. The recommendation aligns with that of the Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP). The number of new cases of HepB infection has decreased by more than 90% since the introduction of hepatitis B immunization in 1982. Unfortunately, about 1,000 U.S. infants acquire HepB perinatally each year. These infants face up to a 90% chance of chronic HepB infection. If untreated, about 25% will die of Hepatocellular Carcinoma or liver cirrhosis.

Six Recent Reports On Hepatitis Risks, Elimination Progress
25 August 2017
Recently, the nation of Georgia and the Cherokee Nation in Oklahoma have reported excellent progress toward elimination of hepatitis C among their populations. Additionally, the Alaska Native Tribal Health Consortium announced the elimination of acute hepatitis B and early-onset of Hepatocellular Carcinoma as a public health threat among its pediatric population. The elimination of HBV and HCV in the U.S. and around the globe depends on prevention as much as it does treatment. Hepatitis-related health risks are a topic of concern among researchers. presents recent news on hepatitis elimination and the behavior risk factors involved in transmission.

Chinese Scientists Give Big Boost To Cancer-Killing Virus
28 August 2017
Chinese scientists have found a compound that helped a tumor-targeting virus kill liver cancer more effectively while sparing healthy cells, offering new hope for treating the world’s second most common cancer killer, according to a study published Wednesday.

Rapid Hepatocellular Carcinoma Test Can Be Administered Anywhere
25 August 2017
Researchers at the University of Utah have developed a rapid and highly portable liver cancer screening test, that can be administered anywhere. One of the biggest challenges in treating liver cancer is that often symptoms don’t appear until the disease is in the later stages, meaning it is important that people are tested rapidly when doctors suspect they might have it.

Telomere Length Prognostic In Hepatocellular Carcinoma
24 August 2017
Li-Jie Ma, from Fudan University in Shanghai, and colleagues used telomere-specific fluorescence in situ hybridization and quantitative polymerase chain reaction to assess telomere length in HCC cell lines, tumor tissues, and nontumor cells within the tumor.

Blueprint To Present Early-Stage Data On BLU-554 At Medical Conferences Next Month
21 August 2017
Blueprint Medicines (NASDAQ:BPMC) plans to present updated results from a Phase 1 clinical trial assessing BLU-554 in patients with advanced Hepatocellular Carcinoma (liver cancer) at the European Society for Medical Oncology (ESMO) in Madrid on September 10 and at the 11th Annual International Liver Cancer Association (ILCA) Annual Conference in Seoul, South Korea a week later.

Two Potential Hepatocellular Carcinoma Treatments Get Orphan Drug Designations
16 August 2017
Singapore-based clinical-stage biotechnology company Lion TCR was granted two orphan drug designations today by the U.S. Food and Drug Administration (FDA) for T-cell therapies. HBV-specific TCR redirected T-cell therapies against HCC with transient mRNA and the longer lasting DNA transduction technologies are both in development for the treatment of Hepatocellular Carcinoma (HCC).

Emerging Approaches In Liver Cancer
16 August 2017
Moving the Needle in HCC Video Panel: Panelists: Richard S. Finn, MD, Geffen School of Medicine; Jordi Bruix, MD, Hospital Clinic University of Barcelona; Amit Singal, MD, MSCS, UT Southwestern Medical Center; Richard H. Marshall, MD, University Medical Center New Orleans; Arndt Vogel, MD, PhD, Hanover Medical School.

Immunicum AB Announces Last Patient Last Visit In The Ongoing Phase I/II Hepatocellular Carcinoma Study
15 August 2017
“Today’s announcement continues the significant progress we have made within our clinical programs this year to demonstrate ilixadencel’s therapeutic potential as an off-the-shelf immune primer in solid tumors. HCC in particular is a very severe type of cancer with limited treatment options and a strong demand for novel, innovative therapies such as ilixadencel,” said Peter Suenaert, MD, PhD, Immunicum’s Chief Medical Officer. “Especially in this rapidly advancing type of cancer, the ability to extend survival by even a few months is a positive benefit. The interim results we presented at the SITC Annual meeting last November were promising and we look forward to the complete results, which we hope to communicate before end of year.”

Linda And Deane, Parents Of The Late Chelsea Smith, Fitchburg, With Dr. Alison O’Neill, Pediatric Oncologist, Dana-Farber
15 August 2017
Chelsea passed away in January 2017 at the age of 26. She was treated for hepatoblastoma at 15 months and then at 24 for Hepatocellular Carcinoma due to a liver transplant. She was a patient with Dana-Farber for 24 years and appeared on last year’s Radio-Telethon. Chelsea had two older brothers, Griffin, 31 and Quinn, 28. Chelsea enjoyed spending time with her two nieces. Chelsea loved the beach – she would go there to relax and forget about her diagnosis. She enjoyed spending time with her family and friends. She also loved movies and shows. Last year Chelsea shared: “It’s a very scary time in my life, never knowing what each day will bring. Life is precious to me and I am lucky to be here today. I am also struggling with why this is happening again. After a successful liver transplant, we had a lot of hope for a new beginning and living my life with the least of worries. I am grateful for the liver transplant.”

KMCH Offers Nuclear Medicine Treatment For Liver Cancer
15 August 2017
The Kovai Medical Centre and Hospital has introduced nuclear medicine to treat advanced and inoperable liver cancers. The treatment, called Rhenium 188 Lipiodol, has been found to be effective in extending patients’ lives by at least a year or two, according to a study published by the National Institutes of Health. The treatment is also touted to be as affordable as other existing forms of treatments.

New Liver Cancer Data Have Been Reported By Researchers At General Hospital Of PLA
15 August 2017
New Liver Cancer Data Have Been Reported by Researchers at General Hospital of PLA (Thymidylate synthase gene polymorphisms as important contributors affecting Hepatocellular Carcinoma prognosis.) By a News Reporter-Staff News Editor at Cancer Weekly Fresh data on Oncology – Liver Cancer are presented in a new report. According to news reporting from Beijing, People’s Republic of China, by NewsRx journalists, research stated, “Thymidylate synthase (TYMS), a key rate-limiting enzyme in the folate metabolism, plays essential roles in the development of several malignancies including Hepatocellular Carcinoma (HCC). Nonetheless, the association of the single nucleotide polymorphisms (SNPs) in TYMS gene with the prognosis of Chinese HCC patients remains unknown.”

Individualized Radiotherapy Effective In Liver Cancer
11 August 2017
Individualized adaptive stereotactic body radiation therapy (SBRT) based on liver biomarkers may be highly effective and safe without increasing relapse risk in patients with Hepatocellular Carcinoma who have had pre-existing liver dysfunction, according to a study published in JAMA Oncology.

Gene Study Based On RNA Interference May Lead To New Liver Cancer Therapies
11 August 2017
University of Maryland researchers think they’ve discovered how a specific gene plays a key role in helping liver cancer cells obtain the nutrition necessary to proliferate. Cancer is often treated by starving it by targeting the pathways cancer cells use to meet their energy needs. The laboratory of Hongbing Wang, Ph.D., focuses on this approach as it applies to liver cancer.

Nexavar Receives Final Appraisal For Primary Liver Cancer
10 August 2017
The National Institute for Health and Care Excellence (NICE) has released a Final Appraisal Document (FAD) recommending Nexavar® (sorafenib) for use on NHS England for the treatment of patients with advanced Hepatocellular Carcinoma (HCC) who have a Child-Pugh grade A liver impairment and who have failed or are unsuitable for surgical or loco-regional therapies.

VN’s First Robotic Surgery On Liver Cancer Patient
10 August 2017
Doctors at Bình Dân Hospital in HCM City have performed the country’s first robotic surgery on a liver cancer patient. Doctors removed the left lobe of the liver, which contained a six-centimeter tumor, of a 59-year-old patient from the Mekong Delta province of Long An in late July, according to a hospital press release sent to the media on Wednesday. Robotic surgery is a type of minimally invasive surgery that uses smaller incisions than normal surgical methods. The method helps to protect the liver’s main blood vessel.

Study Shows Universal Vaccination Has Wiped Out Hepatitis B And Associated Liver Cancer In Alaska’s Young People
10 August 2017
“Universal newborn vaccination coupled with mass screening and immunization of susceptible people has eliminated early ­onset HCC and acute symptomatic HBV infection as a public health threat among children. This population­ based approach can serve as a model for other populations.” They conclude: “The elements of this program that we introduced — which include screening and interventions to reduce perinatal transmission and universal vaccination — are recommended as the standard of care for all US populations, including Indigenous populations. Elimination in other populations, however, depends on the how effectively those interventions are applied, which might not be as comprehensive as took place in the tribal system.”

Frontier Pharma: Liver Cancer — Identifying And Commercializing First-In-Class Innovation
10 August 2017
Liver plays various vital roles within the body, including the removal of toxins from the blood, the production of bile to help digest fat and substances to help blood clot, in addition to making, storing and releasing sugar for energy. Primary liver cancer is a cancer that originates in the liver. Several histological subtypes make up liver cancer. The primary subtype is Hepatocellular Carcinoma (HCC), which accounts for approximately 80-90% of all cases (Nordenstedt et al., 2010). Others include cholangiocarcinoma, hepatoblastoma and hemangiosarcoma (McGlynn and London, 2011). As subtypes other than HCC are significantly less common, a substantial portion of clinical and commercial focus revolves around HCC.

CARsgen Launches First-In-Class Anti-Claudin18.2 CAR-T Clinical Trial
10 August 2017
CARsgen Therapeutics, a global leader in developing chimeric antigen receptor T-cell (CAR-T cell) therapies for solid tumors, today announced its first-in-class anti-Claudin18.2-CAR-T cell therapy for gastric and pancreatic cancers has entered into phase-I clinical trial and starts patients recruitment at Changhai Hospital of Shanghai, a renowned hospital of global reputation for expertise on gastroesophageal and related cancer.

Identifying A New Type Of Liver Tumor
9 August 2017
Investigators at Children’s Hospital Los Angeles have succeeded in better defining a rare pediatric malignant liver disease—a necessary step in achieving an optimum treatment. The research into hepatocellular malignant neoplasm-NOS (HEMNOS) is the largest case study of its kind to date. HEMNOS is a recently described entity that has features of the most common pediatric liver cancer—hepatoblastoma (HB), and Hepatocellular Carcinoma (HCC)—a liver cancer more commonly seen in adults.

Exelixis, Inc. Continued Its Winning Ways And Rose 10% In July Thanks To These Three Catalysts
9 August 2017
Bristol-Myers Squibb and Exelixis announced that they had commenced a phase 3 trial known as CheckMate 9ER that’ll evaluate the combination of Bristol-Myers’ cancer immunotherapy Opdivo in combination with Exelixis’ Cabometyx as a first-line treatment for advanced renal cell carcinoma (RCC) versus the current standard-of-care treatment, Sutent. The study will also examine the combination of Bristol-Myers’ Opdivo and Yervoy with Cabometyx in the same indication. Even though Exelixis wowed in the phase 2 Cabosun study in first-line advanced RCC, any added label indications that could grow its market share are a welcome sight for investors.

Hong Kong Researcher At Singapore’s National Cancer Centre Discovered GATA4 As The Potential Key Factor In Beating Liver Cancer
7 August 2017
The latest finding by an international study borne by a collaboration between the Cleveland Clinic in the United States and the National Cancer Centre in Singapore revealed a loss of a single gene—GATA4—may drive the development of liver cancer. “Losing the GATA4 gene is like losing one of the main guardians of the liver,” said Timothy Wai-ho Shuen, a Hongkonger who is a research fellow at the National Cancer Centre in Singapore, also one of the key authors of the study.

EMA Clears Bayer’s Stivarga For Liver Cancer
7 August 2017
The European Medicines Agency (EMA) approved oral multikinase inhibitor Stivarga (regorafenib) for patients with HCC who have been treated first-line with Bayer’s older drug Nexavar (sorafenib), matching the drug’s approval in the US in April and Japan in June. “Nexavar is the only approved first-line treatment and Stivarga the only approved second-line therapy in Europe and the US for patients with HCC,” said Bayer in a statement. HCC is the most common form of liver cancer, which is often more difficult to treat than other cancers with an annual mortality rate of 48,000 in the EU.

Hong Kong Scientist Helps Find Missing Gene Key To Liver Cancer
1 August 2017
Liver cancer patients could be given drugs that are more effective in future after an international study involving a Hong Kong scientist discovered how a missing gene plays a key factor in the development of the disease. More than 80 per cent of cases are in Asia and it is the third deadliest cancer in Hong Kong. The research team, comprised of scientists from the National Cancer Centre Singapore and the Cleveland Clinic in the United States, linked the absence of the GATA4 gene to the growth of cancerous cells in patients.

For past liver cancer news, please visit our Liver Cancer News Archives.

Scroll Up